IRON-CHELATING AGENTS IN NON-IRON OVERLOAD CONDITIONS

被引:67
作者
VOEST, EE
VREUGDENHIL, G
MARX, JJM
机构
[1] UNIV HOSP UTRECHT, DEPT INTERNAL MED, 3508 GA UTRECHT, NETHERLANDS
[2] UNIV HOSP NIJMEGEN, 6500 HB NIJMEGEN, NETHERLANDS
关键词
D O I
10.7326/0003-4819-120-6-199403150-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To review the current clinical experience with iron chelators in non-iron overload conditions. Data Sources: The English-language literature was searched from 1983 through 1992 manually and using MEDLINE. Study Selection: Original articles, case reports, and abstracts addressing iron chelation. Data Extraction: Selected reports that described clinical applications of iron chelators in non-iron overload conditions were classified according to their stated mechanism of interference with disease activity. Articles stating the rationale for clinical use of iron chelators were also included. Results: Iron chelators were used in non-iron overload conditions to produce antioxidant effects, antiproliferative effects, and antiprotozoal effects and for aluminum chelation. In addition, several reports described singular observations in various diseases. Deferoxamine is the only iron chelator available for clinical studies. The treatment-related (side) effects appear to be associated with patient iron levels. Conclusions: Randomized clinical trials are needed to confirm the promising effects of iron chelators in non-iron overload conditions. Oral iron chelators with fewer toxic effects are especially needed.
引用
收藏
页码:490 / 499
页数:10
相关论文
共 150 条
[1]   IRON AND FOLATE STATUS IN GAMBIAN CHILDREN WITH MALARIA [J].
ABDALLA, SH .
ANNALS OF TROPICAL PAEDIATRICS, 1990, 10 (03) :265-272
[2]   ORAL IRON CHELATION WITH L1 [J].
AGARWAL, MB ;
VISWANATHAN, C ;
RAMANATHAN, J ;
MASSIL, DE ;
SHAH, S ;
GUPTE, SS ;
VASANDANI, D ;
PUNIYANI, RR .
LANCET, 1990, 335 (8689) :601-601
[3]  
AGARWAL MB, 1991, NOV INT C OR IR CHEL
[4]   TOXICITY OF TUBULE FLUID IRON IN THE NEPHROTIC SYNDROME [J].
ALFREY, AC .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (04) :F637-F641
[5]  
ALTMANN P, 1988, LANCET, V1, P1012
[6]   IMPROVEMENT OF POSTISCHEMIC MYOCARDIAL-FUNCTION AND METABOLISM INDUCED BY ADMINISTRATION OF DEFEROXAMINE AT THE TIME OF REFLOW - THE ROLE OF IRON IN THE PATHOGENESIS OF REPERFUSION INJURY [J].
AMBROSIO, G ;
ZWEIER, JL ;
JACOBUS, WE ;
WEISFELDT, ML ;
FLAHERTY, JT .
CIRCULATION, 1987, 76 (04) :906-915
[7]   EFFECT OF IRON CHELATION ON INFLAMMATORY JOINT DISEASE [J].
ANDREWS, FJ ;
MORRIS, CJ ;
KONDRATOWICZ, G ;
BLAKE, DR .
ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (04) :327-333
[8]   THE PROTECTIVE ROLE OF NEOCUPROINE AGAINST CARDIAC DAMAGE IN ISOLATED PERFUSED RAT HEARTS [J].
APPELBAUM, YJ ;
KUVIN, J ;
BORMAN, JB ;
URETZKY, G ;
CHEVION, M .
FREE RADICAL BIOLOGY AND MEDICINE, 1990, 8 (02) :133-143
[9]   OCULAR CHANGES IN PATIENTS UNDERGOING LONG-TERM DESFERRIOXAMINE TREATMENT [J].
ARDEN, GB ;
WONKE, B ;
KENNEDY, C ;
HUEHNS, ER .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1984, 68 (12) :873-877
[10]   LONG-TERM CHELATION THERAPY IN THALASSEMIA MAJOR - EFFECT ON LIVER IRON CONCENTRATION, LIVER HISTOLOGY, AND CLINICAL PROGRESS [J].
BARRY, M ;
FLYNN, DM ;
LETSKY, EA ;
RISDON, RA .
BMJ-BRITISH MEDICAL JOURNAL, 1974, 2 (5909) :16-20